Division of Endo International PLC
Latest From Qualitest Pharmaceuticals
J&J is teaming with Achillion to produce a combo regimen for hepatitis C that might compete with offerings from Gilead, AbbVie and Merck. Amgen is dropping out of its collaboration on brodalumab with AstraZeneca due to concerns about suicidality in clinical trials.
After losing out on Salix to competitor Valeant, Endo makes a strong move into sterile injectables and other alternative dosage forms, and positions itself as the No. 5 generics firm in the U.S.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced May and June 2014.
Endo expanded its generics business by purchasing Dava, EMD Serono partnered with Mersana on antibody-drug conjugates and Ligand in-licensed a cancer and autoimmune disease candidate from TG Therapeutics. It was all part of a hectic deal-making week coinciding with the annual BIO conference in San Diego.
- Generic Drugs
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Endo International PLC
- Senior Management
- Contact Info
Phone: (800) 444-4011
130 Vintage Dr.
Huntsville, AL 35811
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.